RxDoctor Payments Data

Charles Licata, DO

Internal Medicine · Bristol, CTNPI 1538172523

Payments from drug & device makers

$532in general payments, 2019–2025

Across 36 payments — averaging $14.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$124
  • Pfizer$120
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$59
  • Merck$50
  • Johnson & Johnson$26
  • Amarin Pharma, Inc.$24
  • plus $129 from 8 others

What the payments were for

  • Food & beverage$51296%
  • Education$204%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$532 in reported general payments places this provider in the 70th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$46,938
Medicare patients
218
Services billed
1,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$105,915
JardianceEmpagliflozin61$89,037
JanuviaSitagliptin Phosphate43$49,104
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$44,775
OzempicSemaglutide36$42,646
TrulicityDulaglutide20$31,359
XareltoRivaroxaban12$20,043
Tresiba Flextouch U-100Insulin Degludec23$18,664
TradjentaLinagliptin17$17,495
VascepaIcosapent Ethyl25$10,320
Rosuvastatin Calcium520$7,289
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$5,577
Atorvastatin Calcium475$4,041
Levothyroxine Sodium354$3,762
SynthroidLevothyroxine Sodium32$2,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$124$106,53278 claims
PfizerEliquis$120$105,91588 claims
MerckJanuvia$50$49,10443 claims
GSKTrelegy Ellipta$16$44,77538 claims
Novo NordiskOzempic$21$42,64636 claims
Johnson & JohnsonXarelto$26$20,04312 claims
AbbVieSynthroid$13$2,97732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Bristol

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →